Today Medsafe announces its decision to renew the provisional approval for the Pfizer COVID-19 vaccine, says Medsafe Group Manager Chris James.
The renewal of provisional approval is for a period of two years, until 3 November 2023. “Pfizer has met all obligations required to date by the conditions of the provisional approval granted in February this year.
This included providing additional data about the clinical trials and vaccine monitoring. “By renewing the provisional approval, we will continue to receive and assess data from Pfizer about the administration of the vaccine around the world,” says Mr James.
He says that during the two-year renewal period, Medsafe may grant full approval at any time, once Pfizer has submitted a relevant